Role of acetylation in HIV transcription regulation
Official title: Role of Factor Acetylation in the Regulation of HIV Transcription
Funded at J. David Gladstone Institutes · NIH-11360206 · Data updated 2026-11-12
Researchers are studying how specific protein modifications (acetylation) control HIV latency and reactivation, with the goal of guiding new ways to achieve a functional cure.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $737,100 |
| NIH project number | 5R37AI083139-17 |
| Project ID | NIH-11360206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to patient participation in this basic science project.
✕Less likely to help
Direct patient participation is not required for this basic science grant.
What this research studies
This project focuses on how acetylation readers like BRD4 and RPRD1 influence whether HIV stays latent or becomes active. It will test a model where sBET/BAF, MOF, SMYD5, and related factors coordinate to silence or reactivate the virus after integration. The work involves laboratory experiments to map the cascade of events that establish latency and to understand how these proteins recognize acetylated marks on RNA polymerase II and chromatin. Findings could highlight new targets for drugs that maintain latency or selectively reactivate virus for clearance. The study is anchored at the Gladstone Institutes in San Francisco under a defined 5-year timeline.
Why it matters
Potential benefit: If successful, the research could identify new targets to help achieve durable control or cure strategies for HIV.
How similar studies have gone: Prior work has shown that chromatin readers and acetylation marks influence viral latency, supporting the potential relevance of this approach.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Ott, Melanie Maria — J. David Gladstone Institutes
- Study coordinator: Ott, Melanie Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.